-- 根据FactSet调查的分析师报告，GE医疗科技（GEHC）的平均评级为“增持”，平均目标价为80.06美元。 （报道北美、亚洲和欧洲主要银行及研究机构的股票、商品和经济研究。研究机构可通过以下链接联系我们：https://www..com/contact-us）
Price: $60.02, Change: $+0.53, Percent Change: +0.89%
Related Articles
Research
Research Alert: The Clorox Company Beats Estimates Driven By Household And International
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:CLX reported Q3 FY 26 net sales of $1.67B, flat Y/Y with organic sales down 1%, while adj. EPS of $1.64 grew 13% and beat consensus by $0.10. Gross margin contracted 140 bps to 43.2% due to elevated manufacturing costs and unfavorable mix, though disciplined expense management supported earnings. Mixed segment performance showed Household and International delivering growth of 3% and 8%, respectively, while Lifestyle declined 9% on lower consumption and inventory adjustments. Management updated FY 26 guidance expecting net sales to decline ~6% with organic sales down ~9%, including a 7.5%-pt ERP headwind. Adj. EPS guidance of $5.45-$5.65 represents a 27%-29% decline, with gross margin expected to contract 250-300 bps from GOJO inventory step-up and elevated energy costs. The April 1 GOJO acquisition expands the health portfolio though near-term integration costs pressure results. We believe the completed $580M digital transformation positions CLX for long-term operational improvements despite macro headwinds.
$CLX
Research
Research Alert: Rivn: Q1 Eps Ahead Of Consensus; 2026 Guidance Unchanged
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:Rivian (RIVN) posted Q1 adjusted EPS of -$0.55 vs. -$0.41, ahead of the -$0.60 consensus. Revenue rose 11% to $1.38B ($10M ahead of consensus) on a 20% increase in total vehicle sales to 10,365 units, augmented by a 49% Y/Y increase in software and services revenue to $473M. RIVN's gross margin contracted 800 bps to 8.6%, but was ahead of the 8.4% consensus. The quarter's financial results reflect the company's strategic pivot toward broader market accessibility with the R2, though at the cost of near-term profitability. RIVN maintained prior 2026 guidance for adjusted EBITDA, vehicle deliveries, and capex. The company ended Q1 with cash of $4.8B, down from $6.1B at year-end 2025. Shares are trading 1% higher in after-hours trading. RIVN's Q1 earnings were ahead of expectations, although cash burn remains a key concern, with free cash flow deteriorating, driven by increased operating expenses and working capital consumption. Execution risks remain high given challenging demand facing the broader EV industry.
$RiVN
Research
Research Alert: Rmd Posts Mixed Q3 Fy 26 With Solid Margin Expansion Despite Revenue Miss
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:ResMed delivered mixed Q3 FY 26 results with revenue growing 11% to $1.43B, $20M below expectations, while non-GAAP EPS of $2.86 rose 21%, beating consensus by $0.06. Geographic performance showed broad strength with U.S./Canada/Latin America up 9% and Europe/Asia expanding 16%, while masks/accessories outpaced devices with 16% vs 9% growth. The standout highlight was gross margin expansion of 290 bps to 62.2% driven by manufacturing efficiencies and component cost improvements, demonstrating operational excellence in our view. The company continues advancing its digital health strategy with new product launches including the AirTouch F30i mask and plans for a 2027 Indiana distribution center. We expect the recently completed VirtuOx acquisition to strengthen diagnostic capabilities within ResMed's digital health ecosystem across 140+ countries, positioning the company well for continued growth in the expanding sleep and respiratory care market.
$RMD